Related Experiment Video

Updated: Aug 3, 2026

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Complete molecular remission of chronic eosinophilic leukemia complicated by CNS disease after targeted therapy with

Norbert Frickhofen1, Elisabeth Märker-Hermann, Andreas Reiter

  • 1Department of Hematology/Oncology, Dr.-Horst-Schmidt-Kliniken GmbH, Wiesbaden, Germany. norbert.frickhofen@hsk-wiesbaden.de

Annals of Hematology
|February 27, 2004
PubMed

Insights

Chronic eosinophilic leukemia (CEL) can now be diagnosed using genetic markers. A patient with CEL and central nervous system issues responded well to imatinib due to a specific genetic mutation.

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • Distinguishing hypereosinophilic disorders requires identifying clonal hematopoiesis.
  • Chronic eosinophilic leukemia (CEL) is a distinct diagnosis characterized by specific genetic markers.

Observation:

  • A 33-year-old male presented with central nervous system (CNS) involvement, a rare manifestation of CEL.
  • The patient exhibited a remarkable clinical response to low-dose imatinib (Gleevec).

Findings:

  • Molecular profiling revealed constitutive activation of the platelet-derived growth factor receptor-alpha (PDGFR-A).
  • This PDGFR-A activation was identified as the underlying mechanism for imatinib sensitivity.

Implications:

  • This case highlights the importance of molecular diagnostics in classifying hypereosinophilic disorders.
  • Targeted therapy with imatinib can be effective for CEL patients with PDGFR-A alterations, even with CNS involvement.

More Related Videos

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...